Company intelligence / Profile preview
Sōlaria Biō
Cambridge, Massachusetts, United Statessolareabio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead product SBD111 clinically validated to slow bone loss (pending peer review & publication); other pipeline assets addressing arthritis and aging are in preclinical and development stages[2][6].
- Therapeutic areas
- EndocrinologyImmunologyRheumatologyOther
- Modalities
- Live biotherapeutic product therapyMicrobial therapyDietary supplement (therapeutic food/medical food)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ADM (Archer Daniels Midland) – technology licensing for use in novel food and beverage matrices[3]
Beyond the preview
Go deeper on Sōlaria Biō.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sōlaria Biō.